vs
Side-by-side financial comparison of Amgen (AMGN) and McKesson Corporation (MCK), based on the latest 10-Q / 10-K filings. Click either name above to swap in a different company.
McKesson Corporation is the larger business by last-quarter revenue ($106.2B vs $9.9B, roughly 10.8× Amgen). Amgen runs the higher net margin — 13.5% vs 1.1%, a 12.4% gap on every dollar of revenue. On growth, McKesson Corporation posted the faster year-over-year revenue change (11.4% vs 8.6%). McKesson Corporation produced more free cash flow last quarter ($1.1B vs $961.0M). Over the past eight quarters, McKesson Corporation's revenue compounded faster (17.9% CAGR vs 15.1%).
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics.
McKesson Corporation is an American publicly traded company that distributes pharmaceuticals and provides health information technology, medical supplies, and health management tools. The company delivers a third of all pharmaceutical products used or consumed in North America and employs over 80,000 employees. With $308.9 billion in 2024 revenue, it is the ninth-largest company by revenue in the United States and the nation's largest health care company.
AMGN vs MCK — Head-to-Head
Income Statement — Q4 2025 vs Q3 2026
| Metric | | |
|---|---|---|
| Revenue | $9.9B | $106.2B |
| Net Profit | $1.3B | $1.2B |
| Gross Margin | 69.8% | 3.5% |
| Operating Margin | 27.6% | 1.5% |
| Net Margin | 13.5% | 1.1% |
| Revenue YoY | 8.6% | 11.4% |
| Net Profit YoY | 112.6% | 34.9% |
| EPS (diluted) | $2.45 | $9.59 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align — see 8-quarter trend below.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history — bar widths are scaled to the larger of the two companies so you can eyeball the size gap and growth trajectory without doing math. Quarters aligned by calendar period (report date) so offset fiscal years line up.
| Q4 25 | $9.9B | $106.2B | ||
| Q3 25 | $9.6B | $103.2B | ||
| Q2 25 | $9.2B | $97.8B | ||
| Q1 25 | $8.1B | $90.8B | ||
| Q4 24 | $9.1B | $95.3B | ||
| Q3 24 | $8.5B | $93.7B | ||
| Q2 24 | $8.4B | $79.3B | ||
| Q1 24 | $7.4B | $76.4B |
| Q4 25 | $1.3B | $1.2B | ||
| Q3 25 | $3.2B | $1.1B | ||
| Q2 25 | $1.4B | $784.0M | ||
| Q1 25 | $1.7B | $1.3B | ||
| Q4 24 | $627.0M | $879.0M | ||
| Q3 24 | $2.8B | $241.0M | ||
| Q2 24 | $746.0M | $915.0M | ||
| Q1 24 | $-113.0M | $791.0M |
| Q4 25 | 69.8% | 3.5% | ||
| Q3 25 | 67.8% | 3.4% | ||
| Q2 25 | 67.2% | 3.4% | ||
| Q1 25 | 63.6% | 4.0% | ||
| Q4 24 | 65.7% | 3.4% | ||
| Q3 24 | 61.1% | 3.5% | ||
| Q2 24 | 61.4% | 4.0% | ||
| Q1 24 | 57.0% | 4.7% |
| Q4 25 | 27.6% | 1.5% | ||
| Q3 25 | 26.4% | 1.4% | ||
| Q2 25 | 28.9% | 1.1% | ||
| Q1 25 | 14.5% | 1.8% | ||
| Q4 24 | 25.4% | 1.3% | ||
| Q3 24 | 24.1% | 0.6% | ||
| Q2 24 | 22.8% | 1.3% | ||
| Q1 24 | 13.3% | 1.6% |
| Q4 25 | 13.5% | 1.1% | ||
| Q3 25 | 33.7% | 1.1% | ||
| Q2 25 | 15.6% | 0.8% | ||
| Q1 25 | 21.2% | 1.4% | ||
| Q4 24 | 6.9% | 0.9% | ||
| Q3 24 | 33.3% | 0.3% | ||
| Q2 24 | 8.9% | 1.2% | ||
| Q1 24 | -1.5% | 1.0% |
| Q4 25 | $2.45 | $9.59 | ||
| Q3 25 | $5.93 | $8.92 | ||
| Q2 25 | $2.65 | $6.25 | ||
| Q1 25 | $3.20 | $9.90 | ||
| Q4 24 | $1.17 | $6.95 | ||
| Q3 24 | $5.22 | $1.87 | ||
| Q2 24 | $1.38 | $7.00 | ||
| Q1 24 | $-0.21 | $6.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest filing — the kind of financial-strength check premium terminals charge for.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $9.1B | $3.0B |
| Total DebtLower is stronger | $54.6B | $5.4B |
| Stockholders' EquityBook value | $8.7B | $-1.3B |
| Total Assets | $90.6B | $84.2B |
| Debt / EquityLower = less leverage | 6.31× | — |
8-quarter trend — quarters aligned by calendar period so offset fiscal years match up.
| Q4 25 | $9.1B | $3.0B | ||
| Q3 25 | $9.4B | $4.0B | ||
| Q2 25 | $8.0B | $2.4B | ||
| Q1 25 | $8.8B | $5.7B | ||
| Q4 24 | $12.0B | $1.1B | ||
| Q3 24 | $9.0B | $2.5B | ||
| Q2 24 | $9.3B | $2.3B | ||
| Q1 24 | $9.7B | $4.6B |
| Q4 25 | $54.6B | $5.4B | ||
| Q3 25 | $54.6B | $6.0B | ||
| Q2 25 | $56.2B | $6.5B | ||
| Q1 25 | $57.4B | $4.5B | ||
| Q4 24 | $60.1B | $4.4B | ||
| Q3 24 | $60.4B | $5.7B | ||
| Q2 24 | $62.6B | $5.6B | ||
| Q1 24 | $64.0B | $5.6B |
| Q4 25 | $8.7B | $-1.3B | ||
| Q3 25 | $9.6B | $-1.7B | ||
| Q2 25 | $7.4B | $-2.0B | ||
| Q1 25 | $6.2B | $-2.1B | ||
| Q4 24 | $5.9B | $-3.1B | ||
| Q3 24 | $7.5B | $-3.0B | ||
| Q2 24 | $5.9B | $-1.8B | ||
| Q1 24 | $5.0B | $-2.0B |
| Q4 25 | $90.6B | $84.2B | ||
| Q3 25 | $90.1B | $84.2B | ||
| Q2 25 | $87.9B | $81.3B | ||
| Q1 25 | $89.4B | $75.1B | ||
| Q4 24 | $91.8B | $71.1B | ||
| Q3 24 | $90.9B | $72.4B | ||
| Q2 24 | $90.9B | $71.7B | ||
| Q1 24 | $93.0B | $67.4B |
| Q4 25 | 6.31× | — | ||
| Q3 25 | 5.67× | — | ||
| Q2 25 | 7.57× | — | ||
| Q1 25 | 9.24× | — | ||
| Q4 24 | 10.23× | — | ||
| Q3 24 | 8.02× | — | ||
| Q2 24 | 10.57× | — | ||
| Q1 24 | 12.75× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Net income can be massaged; cash flow is harder to fake.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.6B | $1.2B |
| Free Cash FlowOCF − Capex | $961.0M | $1.1B |
| FCF MarginFCF / Revenue | 9.7% | 1.1% |
| Capex IntensityCapex / Revenue; lower = less reinvestment burden | 6.5% | 0.1% |
| Cash ConversionOCF / Net Profit; >1× = earnings back up with cash | 1.20× | 1.04× |
| TTM Free Cash FlowTrailing 4 quarters | $8.1B | $10.0B |
8-quarter trend — quarters aligned by calendar period so offset fiscal years match up.
| Q4 25 | $1.6B | $1.2B | ||
| Q3 25 | $4.7B | $2.4B | ||
| Q2 25 | $2.3B | $-918.0M | ||
| Q1 25 | $1.4B | $7.7B | ||
| Q4 24 | $4.8B | $-2.4B | ||
| Q3 24 | $3.6B | $2.1B | ||
| Q2 24 | $2.5B | $-1.4B | ||
| Q1 24 | $689.0M | $4.1B |
| Q4 25 | $961.0M | $1.1B | ||
| Q3 25 | $4.2B | $2.3B | ||
| Q2 25 | $1.9B | $-1.0B | ||
| Q1 25 | $980.0M | $7.6B | ||
| Q4 24 | $4.4B | $-2.5B | ||
| Q3 24 | $3.3B | $2.0B | ||
| Q2 24 | $2.2B | $-1.5B | ||
| Q1 24 | $459.0M | $4.0B |
| Q4 25 | 9.7% | 1.1% | ||
| Q3 25 | 44.4% | 2.2% | ||
| Q2 25 | 20.8% | -1.1% | ||
| Q1 25 | 12.0% | 8.3% | ||
| Q4 24 | 48.4% | -2.6% | ||
| Q3 24 | 39.0% | 2.1% | ||
| Q2 24 | 26.5% | -1.9% | ||
| Q1 24 | 6.2% | 5.2% |
| Q4 25 | 6.5% | 0.1% | ||
| Q3 25 | 4.6% | 0.1% | ||
| Q2 25 | 4.0% | 0.1% | ||
| Q1 25 | 5.0% | 0.2% | ||
| Q4 24 | 4.1% | 0.1% | ||
| Q3 24 | 3.0% | 0.1% | ||
| Q2 24 | 2.8% | 0.1% | ||
| Q1 24 | 3.1% | 0.2% |
| Q4 25 | 1.20× | 1.04× | ||
| Q3 25 | 1.46× | 2.18× | ||
| Q2 25 | 1.59× | -1.17× | ||
| Q1 25 | 0.80× | 6.15× | ||
| Q4 24 | 7.61× | -2.71× | ||
| Q3 24 | 1.26× | 8.71× | ||
| Q2 24 | 3.30× | -1.51× | ||
| Q1 24 | — | 5.24× |
Financial Flow Comparison
Sankey diagram of revenue → gross profit → operating profit → net profit for each company. Charts shown full-width and stacked so both segment hierarchies are readable side-by-side on desktop and mobile.
Revenue Breakdown by Segment
AMGN
| Products | $9.4B | 95% |
| Xgeva | $291.0M | 3% |
| Vectibix | $163.0M | 2% |
| Aranesp | $115.0M | 1% |
MCK
| North American Pharmaceutical Segment | $88.3B | 83% |
| Oncology And Multispecialty Segment | $13.0B | 12% |
| Medical Surgical Solutions Segment | $3.0B | 3% |
| Prescription Technology Solutions Segment | $1.5B | 1% |
